Navigation Links
Regulus Therapeutics Initiates an Orphan and Rare Disease microRNA Therapeutic Effort in Brain Cancer
Date:12/12/2011

omising collaborative approach."

 

Glioblastoma multiforme, also known as glioblastoma or grade IV astrocytoma, is a fast growing brain tumor that forms from glial (supportive) tissue of the brain.  GBM is the most prevalent form of primary brain tumor and peak incidence is in adults between 45 and 70 years.  Treatment options are limited and survival is little over one year. GBM is considered a rare, or orphan, disease with an incidence in the U.S. of approximately 12,000 per year.

 

Regulus is advancing multiple microRNA therapeutic programs to the clinic in the areas of fibrosis, HCV infection, immuno-inflammatory disease, metabolic disease, and oncology.

 

About microRNAs

The discovery of microRNA in humans during the last decade is one of the most exciting scientific breakthroughs in recent history. microRNAs are small RNA molecules, typically 20 to 25 nucleotides in length, that do not encode proteins but instead regulate gene expression. More than 700 microRNAs have been identified in the human genome, and over one-third of all human genes are believed to be regulated by microRNAs. A single microRNA can regulate entire networks of genes. As such, these molecules are considered master regulators of the human genome. microRNAs have been shown to play an integral role in numerous biological processes, including the immune response, cell-cycle control, metabolism, viral replication, stem cell differentiation and human development. Most microRNAs are conserved across multiple species, indicating the evolutionary importance of these molecules as modulators of critical biological pathways. Indeed, microRNA expression, or function, has been shown to be significantly altered in many disease states, including cancer, heart failure and viral infections. Targeting microRNAs with anti-miRs, antisense oligonucleotide inhibitors of mic
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33
2. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
3. Regulus Therapeutics to Present New Advancements in microRNA Therapeutics for Treatment of Metabolic Diseases and Cancer
4. Webinar Advisory: Regulus to Host Discussion About Potential of microRNA-33 as Target for Treatment of Atherosclerosis
5. Regulus Therapeutics Expands Worldwide Patent Coverage on microRNA-122 to Treat Hepatitis C Virus (HCV) Infection
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Show organisers ... Health Expo 2014 were a brand new ... London , plus a 10% ...        (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ...      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)...  Breg, Inc., a premier provider of sports ... knee brace with new innovations to help people, ... to active lifestyles.  FreeRunner,s patent-pending design acts on ... when patients need it most, and the ability ... Patellofemoral issues are the most common cause of ...
(Date:7/10/2014)... 10, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... has completed the sale to Galderma of all rights ... held by Valeant for $1.4 billion in cash, pursuant ... recently completed its acquisition of Galderma. ... products to a company that is firmly committed to ...
Breaking Medicine Technology:UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... SAN DIEGO, Feb. 5 ADVENTRX Pharmaceuticals, Inc. (NYSE ... patient enrollment in its bioequivalence study of ANX-514 (docetaxel ... announce results from this study in the second quarter ... chemotherapeutic agent, Taxotere(R), an anti-cancer agent that is approved ...
... to monitor health outcomes in Fresno, California LOS ALTOS, ... Foundation (GHRF) today announced that it has received a ... treatment in California,s Central Valley, a region with the ... grant will help fund data collection and analysis at ...
Cached Medicine Technology:ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 2ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study 3Global Health Research Foundation Awarded $25,000 Grant From Westly Foundation to Study Asthma in California's Central Valley 2
(Date:7/13/2014)... in The Lancet Neurology calls for ... term neurological problems that repeated concussions can cause. ... of sports-related traumatic brain injury (TBI), and the ... amyotrophic lateral sclerosis, and other neurological disorders, say ... concerning, is that even when the symptoms of ...
(Date:7/13/2014)... 13, 2014 Carolinas Healthcare System celebrated ... the Carolinas HealthCare System - Anson located in Anson ... Anson Community Hospital in Wadesboro. , Located on U.S. ... from the previous facility. Situated on a 10-acre site, ... an emergency room drop-off, helipad, healing garden, and 15 ...
(Date:7/13/2014)... portable, microchip-based test for diagnosing type-1 diabetes could ... understand the disease, according to the device,s inventors ... Described in a paper to be published online ... test employs nanotechnology to detect type-1 diabetes outside ... two main forms of diabetes mellitus, which are ...
(Date:7/13/2014)... Victorian Hotel has recently announced that it ... bikes for its "Cycle the City" program, which encourages ... the area using a rental bicycle, available for just ... call Vancouver home, as it is a city with ... journeys through the countryside. Vancouver hotel rooms often play ...
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
Breaking Medicine News(10 mins):Health News:Carolinas HealthCare System - Anson Hospital Now Open 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 2Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 3Health News:Stanford researchers invent nanotech microchip to diagnose type-1 diabetes 4Health News:Victorian Hotel Creates Excitement by Adding "Cycle the City" Bike Rentals for Its Vancouver Hotel Rooms 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4
... high health-care costs it has become a burden both on ... as a respite comes a new cardio drug that negates ... ,The drug is in the African-American heart failure patients where ... Angus, M.D., M.P.H., professor of critical care medicine at the ...
... A liver transplant operation has been conducted on a six-year-old ... underwent the surgery celebrates his birthday on 19 December 2005. ... 'The kid is still in ICU but is responding well ... hope his condition will be normal soon.' , ,He ...
... Clinic say that the flagship breast cancer drug, tamoxifen might ... genetic variation. // ,This particular variant gene has the ... is vital to activate tamoxifen against breast cancer. The study ... of Michigan Comprehensive Cancer Center and Matthew Goetz, M.D., an ...
... is responsible for the death of Rene Anderson, a diabetic ... was prescribed to Mrs. Anderson to ease the numbness and ... // ,The medicine is reported to have resulted disturbed ... an intoxicated and confused state. Here her condition continued to ...
... formed a new cabinet committee to plan strategies to fight ... said that though the United Kingdom //Government has taken various ... spread but the committee feels still a lot has to ... committee feels that the Government should organize the food sector ...
... easily subsided by administering sweet to children now has a ... ,They have reported that the analgesic efficacy of sweet ... sweet taste and by the child's weight status. This appears ... just because they taste good, but also because sweets make ...
Cached Medicine News:Health News:A cost effective heart failure drug hits the market! 2Health News:Sweet pain releiver! 2
... Workstations provide comprehensive neurological monitoring in ... unit to accurately access your patients ... 15 years experience, and a long ... neurological monitoring systems have a proven ...
Vikingselect™ Intra-Operative Monitoring (IOM)....
The Nicolet Bravo™ is a Multi-application system that can configure to meet the needs of neurophysiology department....
... system especially designed for surgical monitoring and ... channels and is equipped with two headboxes ... can be independently configured as either a ... Endeavor amplifiers are based on the Firewire ...
Medicine Products: